Ipsen Pays Exelixis $200m Up Front For Ex-US Cometriq Rights

Exelixis Inc. will bring in $260m in up front and milestone payments in 2016 alone under its new partnership with Ipsen for ex-US development and commercialization of Cometriq (cabozantinib), while the company awaits both US and EU approvals of the drug for a form of kidney cancer.

Exelixis Inc. will bring in $260m in up front and milestone payments in 2016 alone under its new partnership with Ipsen for ex-US development and commercialization of Cometriq (cabozantinib), while the company awaits both US and EU approvals of the drug for a form of kidney cancer.

Ipsen agreed to pay $200m up front for the rights to Cometriq outside of the US, Canada and Japan plus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category